We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Burnham Announces License Agreement with Johnson & Johnson Pharmaceutical Research & Development
News

Burnham Announces License Agreement with Johnson & Johnson Pharmaceutical Research & Development

Burnham Announces License Agreement with Johnson & Johnson Pharmaceutical Research & Development
News

Burnham Announces License Agreement with Johnson & Johnson Pharmaceutical Research & Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Burnham Announces License Agreement with Johnson & Johnson Pharmaceutical Research & Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Burnham Institute for Medical Research (Burnham) has signed an assay development and license agreement with Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD). The agreement is Burnham's first broad-based partnership with a large pharmaceutical company.

Under this multi-year agreement, Burnham will provide J&JPRD with access to high-throughput assay screening technologies to investigate certain drug targets for inflammatory diseases. Financial terms were not disclosed.

"This collaboration offers great synergies," said Dr. John Reed, Burnham President and CEO, Professor and Donald Bren Presidential Chair. "Burnham has great expertise in finding new targets and screening compounds to identify chemical leads, and I believe this collaboration will foster the discovery of drug products with real clinical potential."
Advertisement